...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction.
【24h】

Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction.

机译：β受体阻滞剂（美托洛尔或普萘洛尔）对辛伐他汀降低急性心肌梗死C反应蛋白的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent data indicated that statin therapy may fail to reduce the incidence of coronary events in patients concomitantly using beta blockers. The aim of the present study was to examine whether the concomitant use of beta blockers would modify the anti-inflammatory action of statins. Changes in C-reactive protein (CRP) between days 1 and 5 after myocardial infarction were evaluated in 189 patients treated with simvastatin alone (S), beta blockers alone (B; propranolol or metoprolol), S + B, or neither of these 2 medications (N) in a prospective observational cohort. At baseline, median CRP was lower in the S group (0.40 mg/dl, interquartile range 0.1 to 0.6) than the other groups (B: 0.6 mg/dl, interquartile range 0.4 to 1.6; S + B: 0.5 mg/dl, interquartile range 0.3 to 1.2; and N: 0.6 mg/dl, interquartile range 0.2 to 1.5). By day 5, median CRP was 1.3 mg/dl (interquartile range 0.7 to 2.6), 4.3 (interquartile range 1.6 to 8.8), 4.6 (interquartile range 2.8 to 9.5), and 4.4 (interquartile range 1.9 to 9.9) for the S, B, S + B, and N groups, respectively. After adjusting for log(e) baseline CRP, the difference in log(e) CRP between days 1 and 5 was significantly lower in the S group compared with the B (-0.74 +/- 0.23 [SE], p = 0.001) or S + B group (-0.99 +/- 0.20 [SE], p <0.0001). The significance remained after adjustment for age, gender, and baseline CRP. There was no significant difference in change in CRP between the SB and B groups. In conclusion, the present study confirmed the anti-inflammatory action of statins and showed that concomitant use of beta blockers may significantly attenuate this effect.
机译：最近的数据表明，他汀类药物疗法可能无法同时使用β受体阻滞剂降低患者冠状动脉事件的发生率。本研究的目的是检查同时使用β受体阻滞剂是否会改变他汀类药物的抗炎作用。评估了189例单独使用辛伐他汀（S），单独使用β受体阻滞剂（B;普萘洛尔或美托洛尔），S + B或两者都不治疗的心肌梗塞后1-5天之间C反应蛋白（CRP）的变化2前瞻性观察队列中的药物（N）。基线时，S组（0.40 mg / dl，四分位间距0.1至0.6）的中位数CRP低于其他组（B：0.6 mg / dl，四分位范围0.4至1.6; S + B：0.5 mg / dl，四分位数范围为0.3至1.2; N：0.6 mg / dl，四分位数范围为0.2至1.5）。到第5天，S的CRP中位数为1.3 mg / dl（四分位数范围1.6至8.8），4.3（四分位数范围1.6至8.8），4.6（四分位数范围2.8至9.5）和4.4（四分位数范围1.9至9.9）， B，S + B和N组。调整log（e）基线CRP后，S组第1天和第5天之间的log（e）CRP差异显着低于B组（-0.74 +/- 0.23 [SE]，p = 0.001）或S + B组（-0.99 +/- 0.20 [SE]，p <0.0001）。在调整了年龄，性别和基准CRP之后，意义仍然存在。 SB组和B组之间的CRP变化无显着差异。总之，本研究证实了他汀类药物的抗炎作用，并表明同时使用β受体阻滞剂可能会大大减弱这种作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号